PI
IOVA icon

PEAK6 Investments’s Iovance Biotherapeutics IOVA Stock Holding History

PEAK6 Investments’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-35,500
Closed -$1.12M – 5413
2021
Q1 		$1.12M Buy
+35,500
New +$1.47M ﹤0.01% 2430

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

PEAK6 Investments's IOVA Position: Q2 2021 in Review

PEAK6 Investments sold out of Iovance Biotherapeutics (IOVA) in Q2 2021, closing a stake of 11,393 shares — an estimated $296K sold.

PEAK6 Investments first reported a position in IOVA in Q1 2021 and held it in 1 quarter. The position peaked at $361K in Q1 2021. 234 funds tracked by Wall St. Rank hold IOVA as of Q2 2021.

  • PEAK6 Investments reported no remaining Iovance Biotherapeutics position as of Q2 2021 after selling out during the quarter.
  • PEAK6 Investments sold 11,393 Iovance Biotherapeutics shares in Q2 2021, an estimated $296K.
  • PEAK6 Investments first reported a position in Iovance Biotherapeutics in Q1 2021 and held it in 1 quarter.
  • PEAK6 Investments's Iovance Biotherapeutics position peaked at $361K in Q1 2021.
  • 234 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2021.

Based on PEAK6 Investments's 13F filing for Q2 2021, filed 13 Aug 2021.